15LBA High tumoral IFNγ mRNA, PD-L1 protein, and combined IFNγ mRNA/PD-L1 protein expression associates with response to durvalumab (anti-PD-L1) monotherapy in NSCLC patients. (September 2015) - Higgs, B.W.; Robbins, P.B.; Blake-Haskins, J.A.; Zhu, W.; Morehouse, C.; Brohawn, P.Z.; Rebelatto, M.C.; Yao, Y.; Jin, X.; Shi, L.; Ranade, K.